Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

R211

—

43b8dc3c-6cd5-59f4-9ef8-c39204666c47

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
overall_survival_months
22
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
  • ANGIOGENESIS+0.510
  • HEDGEHOG_SIGNALING+0.500
  • TGF_BETA_SIGNALING+0.470
  • HYPOXIA+0.410
  • APICAL_JUNCTION+0.400
  • COAGULATION+0.390
  • NOTCH_SIGNALING+0.330
  • GLYCOLYSIS+0.270
  • CHOLESTEROL_HOMEOSTASIS+0.260

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.400
  • UNFOLDED_PROTEIN_RESPONSE-0.150
  • ALLOGRAFT_REJECTION-0.120
  • PROTEIN_SECRETION-0.120
  • OXIDATIVE_PHOSPHORYLATION-0.110
  • SPERMATOGENESIS-0.110
  • MYC_TARGETS_V2-0.090
  • HEME_METABOLISM-0.080
  • KRAS_SIGNALING_DN-0.070

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-77-8146-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.815
2SRR9879274
lung-landscapes@6
—cohortSQ10.789
3TCGA-UY-A8OC-01A-11R-A36F-07
bladder-landscape@3
——0.788
4SRR8943050
bladder-landscape@3
——0.785
5TCGA-60-2708-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.784
6MNG1297
mng-umap@100
——0.780
7SNU449_LIVER
ccle-hcc@v2024.1
HCC—0.777
8TCGA-77-8130-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.769
9SRR8613758
breast-umap@18
—C0.768
1020040086.TNBC
breast-umap@18
—C0.765

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.590Inavolisib— uncovered
ANGIOGENESIS0.510Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.500Inavolisib— uncovered
TGF_BETA_SIGNALING0.470Inavolisib— uncovered
HYPOXIA0.410Idelalisib— uncovered
APICAL_JUNCTION0.400Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
NOTCH_SIGNALING0.330Inavolisib— uncovered
GLYCOLYSIS0.270Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.260Remibrutinib— uncovered
MYOGENESIS0.260Inavolisib— uncovered
UV_RESPONSE_DN0.260Inavolisib— uncovered
DNA_REPAIR0.250Idelalisib— uncovered
E2F_TARGETS0.250Inavolisib— uncovered
MITOTIC_SPINDLE0.220Inavolisib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered
APICAL_SURFACE0.170Temsirolimus— uncovered
G2M_CHECKPOINT0.130Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.120Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.110Inavolisib— uncovered